EMA Authorised: Grepid (clopidogrel (as besilate)) — Pharmathen S.A.

View source ↗

Summary

EMA authorised the drug Grepid, containing clopidogrel besilate, for indications including peripheral vascular diseases, stroke, and myocardial infarction.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction
• Peripheral Vascular Disease
• Stroke

Drugs mentioned

• Grepid (clopidogrel besilate)

Snippet

Status: Authorised. Therapeutic area: Peripheral Vascular Diseases;Stroke;Myocardial Infarction. MAH: Pharmathen S.A.. Decision date: 20/06/2025